| Ms Stacy Blazio, | |
|
401 W Morris Ave, Hammond, LA 70403 | |
| (567) 000-0000 | |
| Not Available |
| Full Name | Ms Stacy Blazio |
|---|---|
| Gender | Female |
| Speciality | Case Manager/care Coordinator |
| Location | 401 W Morris Ave, Hammond, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003338617 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Stacy Blazio, 401 W Morris Ave, Hammond, LA 70403-4121 Ph: (504) 304-3737 | Ms Stacy Blazio, 401 W Morris Ave, Hammond, LA 70403 Ph: (567) 000-0000 |
News Archive
Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.
Nutritionists have since joined with manufacturers to produce supplements using fermentation from this rare mushroom. One such product is CordyMax®, made with a formula recognized in China as the fermented Cordyceps mushroom mycelial product. CordyMax® has been placed under intellectual property protection, and only one company has the license for it outside of China.
American Telemedicine Association Mid-Year Meeting—KORE Telematics, the world's largest digital wireless services provider specializing in machine-to-machine (M2M) communications, today announced that MedApps telehealth solutions are now certified for use on the KORE network.
A new, highly sensitive method to detect genetic variations that initiate colon cancer could be readily used for noninvasive colon cancer screening, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
Targeted Genetics Corporation announced that its partner, Celladon Corporation, presented full data today that show the first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.
› Verified 8 days ago